This primary endpoint was met for the three cohorts of patients, and results have been previously reported. 16 Secondary objectives for Epoch 4 were to evaluate the long-term safety and tolerability of canakinumab, and exploratory objectives included the evaluation of long-term efficacy by assessing the number of flares per patient, the PGA of disease activity and the analysis of Tenofovir alafenamide fumarate CRP and SAA serum levels over time. Patients The detailed inclusion and exclusion criteria for patients in the CLUSTER study have been reported previously.16 Eligible patients with crFMF had a diagnosis of FMF according to Tel Hashomer criteria17 and resistance or intolerance to colchicine. 10?mg/L, while median SAA concentrations remained over the limit of normal (10?mg/L) but under the 30?mg/L threshold. No new or unexpected AEs were reported. Conclusion crFMF patients treated with canakinumab during 72 weeks experienced a minimal incidence of flares and good control of medical disease activity, with no new safety issues reported. gene which encodes pyrin, a protein indicated in cells of the innate immune system.5 6 These mutations lead to excessive activation of the pyrin inflammasome with subsequent launch of large amounts of interleukin 1 beta (IL-1).7 Dysregulated IL-1 takes on a pivotal part in the pathogenesis of FMF.8 According to the current Western League Against Rheumatism (EULAR) recommendations, the aim of FMF treatment is to control acute attacks, minimise chronic subclinical inflammation and its sequelae, mainly secondary amyloidosis, and improve the individuals quality of life (QoL).3 9 Colchicine is the cornerstone of current therapy for FMF; its regular use helps prevent attacks, suppresses chronic subclinical inflammation, helps prevent amyloidosis and enhances QoL.3 10 However, a subset of individuals fail to respond, or are intolerant to colchicine. Several studies have shown that IL-1 inhibition enhances clinical and laboratory features in individuals with colchicine-resistant FMF (crFMF).11C15 Results up to week 40 of the phase III CLUSTER trial (“type”:”clinical-trial”,”attrs”:”text”:”NCT02059291″,”term_id”:”NCT02059291″NCT02059291) shown that canakinumab, a fully human anti-IL-1 monoclonal antibody, was effective to control inflammation and prevent flares in individuals with crFMF.16 Here we statement results from Epoch 4, a 72-week period of open-label treatment designed to study the long-term safety and effectiveness of canakinumab in individuals with crFMF. Methods Study design The CLUSTER study (“type”:”clinical-trial”,”attrs”:”text”:”NCT02059291″,”term_id”:”NCT02059291″NCT02059291, https://clinicaltrials.gov/) evaluated the effectiveness and security of canakinumab in individuals with three recurrent fever syndromes: crFMF, mevalonate kinase deficiency (also known as the hyperimmunoglobulinaemia D syndrome) and the tumour necrosis element receptor-associated periodic syndrome. It included three cohorts of individuals, one per condition, and each cohort adopted the same study design, as previously reported.16 The CLUSTER study was divided in four epochs: a screening period of up to 12 weeks (Epoch 1), a randomised, double-blind, placebo-controlled period of 16 weeks (Epoch 2), a randomised withdrawal, open-label period of 24 weeks Rabbit polyclonal to ZNF394 (Epoch 3), and an open-label treatment period of 72 weeks (Epoch 4). In this article, we report results of individuals with crFMF in Epoch 4 (weeks 41 to 113 of the trial). At the start of Epoch 3, a proportion of the individuals were randomised 1:1 to receive either canakinumab 150?mg or placebo every 8 weeks (q8w), and the rest were treated with open-label canakinumab (150?mg or 300?mg every 4 weeks (q4w)). Individuals going through a flare (defined as physician global assessment (PGA) score Tenofovir alafenamide fumarate 2?and CRP serum levels 30?mg/L) were eligible to start or up-titrate canakinumab up to 300?mg q4w. Therefore, at the Tenofovir alafenamide fumarate end of Epoch 3, individuals were receiving either placebo q8w, canakinumab 150?mg (q4w or q8w) or canakinumab 300?mg (q4w or q8w). Individuals who completed Epoch 3 on placebo came into Epoch 4 and attended scheduled appointments but did not receive canakinumab unless they experienced a flare, in which case they started open-label treatment with canakinumab 150?mg q8w. All other individuals entering Epoch 4 continued on the same canakinumab regimen they were receiving at the end of Epoch 3. If individuals experienced a flare during Epoch 4, stepwise up-titration (ie, 150?mg q8w to 150?mg q4w to 300?mg q4w) was allowed (maximum 300?mg q4w). Down-titration was not allowed in Epoch 4. During the whole study, doses were adjusted by excess weight in individuals with body weight lower than 40?kg, who received canakinumab at either 2?mg/kg (instead of 150?mg) or 4?mg/kg (instead of 300?mg). Most individuals (58/61) were receiving colchicine treatment at study entry, and they were instructed to continue this treatment at a stable dose during the trial. Overall, seven individuals did not take colchicine during Epoch 4, reported reasons were lack of effectiveness (two individuals), lack of tolerability (one patient) and not known (four individuals). Sixty-two centres in 16 countries participated in the study. The institutional review table or self-employed ethics committee at each centre authorized the study. Patients or guardians, as appropriate, offered written educated consent. Objectives The primary objective of the study was to demonstrate that canakinumab treatment at a dose of 150? mg q4w is definitely superior to placebo in achieving a clinically meaningful reduction of disease activity,.